ADAPTIN BIO

Biological preparations for pharmaceuticals; Biological preparations for treatment of cancers, central nervous system diseases and autoimmune disorders; Medical preparations and pharmaceuticals for treatment of cancers, central nervous system diseases and autoimmune disorders; Drug delivery platform technology, namely, drug delivery agents consisting of cellular products that facilitate, enhance or promote optimized delivery of pharmaceutical therapies; Drug delivery agents comprising compounds that facilitate delivery of pharmaceuticals and biotherapeutics; Drug delivery platform comprising of cellular products that facilitate delivery of pharmaceuticals and biotherapeutics; Pharmaceutical preparations for the treatment of cancers, central nervous system diseases and autoimmune disorders using compounds comprising of manipulated immune cells;

Research in the field of biotechnology and pharmaceutical development; Research and development of platform technologies for delivery of therapies; Research and development of platform technologies for delivery of antibody therapies, cell therapies and pharmaceuticals; Research and development regarding the use of immune system cells to discover, research and develop novel platform technologies for delivery of therapies and pharmaceuticals; Pharmaceutical research and development for the treatment of cancers, neurological diseases, and neurological disorders and autoimmune disorders; Scientific research in the field of drug delivery platforms, cell therapies and pharmaceuticals; Pharmaceutical research services; Research and development of pharmaceutical preparations for treatment of cancers, neurological diseases and disorders and autoimmune diseases; Research and development in the fields of pharmaceuticals and biotechnology; Research and development regarding the delivery of drug therapies across the blood-brain barrier and other physiological barriers; Research and development regarding the delivery of drug and cell therapies to targeted body tissue; Research and development regarding the identification and targeting of specific cells for drug therapies;